PL3386500T3 - Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu - Google Patents

Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu

Info

Publication number
PL3386500T3
PL3386500T3 PL16874012.4T PL16874012T PL3386500T3 PL 3386500 T3 PL3386500 T3 PL 3386500T3 PL 16874012 T PL16874012 T PL 16874012T PL 3386500 T3 PL3386500 T3 PL 3386500T3
Authority
PL
Poland
Prior art keywords
benzothiophene
estrogen receptor
selective estrogen
based selective
receptor downregulators
Prior art date
Application number
PL16874012.4T
Other languages
English (en)
Inventor
Gregory R. Thatcher
Rui XIONG
Jiong ZHAO
Debra A. Tonetti
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Publication of PL3386500T3 publication Critical patent/PL3386500T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16874012.4T 2015-12-09 2016-12-09 Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu PL3386500T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264971P 2015-12-09 2015-12-09
US201662322878P 2016-04-15 2016-04-15
PCT/US2016/066023 WO2017100712A1 (en) 2015-12-09 2016-12-09 Benzothiophene-based selective estrogen receptor downregulators

Publications (1)

Publication Number Publication Date
PL3386500T3 true PL3386500T3 (pl) 2023-03-13

Family

ID=59013340

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16874012.4T PL3386500T3 (pl) 2015-12-09 2016-12-09 Selektywne antagonisty receptora estrogenowego na bazie benzotiofenu

Country Status (25)

Country Link
US (7) US20170166551A1 (pl)
EP (2) EP3386968B1 (pl)
JP (2) JP6920709B2 (pl)
KR (1) KR102785173B1 (pl)
CN (2) CN108699024B (pl)
AU (1) AU2016366680B2 (pl)
BR (1) BR112018011607B1 (pl)
CA (1) CA3008020C (pl)
DK (1) DK3386500T3 (pl)
EA (1) EA038180B1 (pl)
ES (1) ES2935125T3 (pl)
HR (1) HRP20221462T1 (pl)
HU (1) HUE061065T2 (pl)
IL (1) IL259566B (pl)
LT (1) LT3386500T (pl)
MX (2) MX393926B (pl)
NZ (1) NZ743651A (pl)
PL (1) PL3386500T3 (pl)
PT (1) PT3386500T (pl)
RS (1) RS63791B1 (pl)
RU (1) RU2747802C2 (pl)
SI (1) SI3386500T1 (pl)
SM (1) SMT202300018T1 (pl)
WO (2) WO2017100715A1 (pl)
ZA (2) ZA201803422B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100715A1 (en) * 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
US10599150B2 (en) 2016-09-29 2020-03-24 The Charles Stark Kraper Laboratory, Inc. Autonomous vehicle: object-level fusion
CA3048057A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
CA3052810A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
EP3749654B1 (en) 2018-02-06 2025-04-23 The Board of Trustees of the University of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
CA3109385A1 (en) * 2018-08-16 2020-02-20 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators to treat medical disorders
US10741313B1 (en) 2019-02-06 2020-08-11 Eaton Intelligent Power Limited Bus bar assembly with integrated surge arrestor
US11249184B2 (en) 2019-05-07 2022-02-15 The Charles Stark Draper Laboratory, Inc. Autonomous collision avoidance through physical layer tracking
KR20220006553A (ko) * 2019-05-09 2022-01-17 사노피 전이성 또는 진행성 유방암 환자에서 사용하기 위한 6-(2,4-디클로로페닐)-5-[4-[(3s)-1-(3-플루오로프로필)피롤리딘-3-일]옥시페닐]-8,9-디하이드로-7h-벤조[7]아눌렌-2-카르복실산
US20220233534A1 (en) * 2019-07-08 2022-07-28 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
MX2022014573A (es) 2020-05-19 2022-12-15 G1 Therapeutics Inc Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos.
CN115710248B (zh) * 2022-11-18 2024-06-21 南京中医药大学 新型选择性雌激素受体下调剂化合物、制备方法及用途
CN116574054B (zh) * 2023-05-15 2025-01-28 南京中医药大学 选择性雌激素受体下调剂化合物、制备方法及用途
WO2025147568A1 (en) * 2024-01-05 2025-07-10 Starton Therapeutics, Inc. Solid state active pharmaceutical compositions for transdermal drug delivery

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1947085A (en) 1931-09-22 1934-02-13 Westinghouse Electric & Mfg Co Electrical apparatus
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE4126999A1 (de) 1991-08-16 1993-02-18 Basf Ag Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JPH05345780A (ja) * 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
CZ285937B6 (cs) 1992-01-16 1999-12-15 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, způsob přípravy těchto derivátů a jejich použití
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
EP0622673B1 (en) 1993-04-24 1998-02-04 Kodak Limited Photographic colour couplers and photographic materials containing them
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
EP0752421B1 (en) 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
PL338555A1 (en) * 1997-08-15 2000-11-06 Univ Duke Method of preventing or treating oestrogen-dependent diseases and disorders
ATE263164T1 (de) 1997-10-03 2004-04-15 Lilly Co Eli Bentzothiophene
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
HK1052877A1 (zh) 2000-07-06 2003-10-03 Wyeth Ssri与雌激素剂之组合
BR0112360A (pt) 2000-07-06 2003-05-06 Wyeth Corp Método para aumentar a atividade da sintase de óxido nìtrico
WO2002003986A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
AU2001271781A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
US6358991B2 (en) 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
CA2414060A1 (en) 2000-07-06 2002-01-17 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2003281632A1 (en) * 2002-07-24 2004-02-09 Eli Lilly And Company Dihydro-dibenzo(b,e)oxepine based selective estrogen receptor modulators, compositions and methods
EP1664052B1 (en) 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
JP2005129430A (ja) 2003-10-27 2005-05-19 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池
FR2862646B1 (fr) * 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
KR20060123186A (ko) 2003-12-15 2006-12-01 라보라뚜와르 떼라멕스 1-엔-페닐-아미노-1에이치-이미다졸 유도체 및 이들을포함하는 약학적 조성물
CA2595477A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
EP1848704A4 (en) 2005-02-14 2011-05-11 Bionomics Ltd Novel tubulin polymerisation inhibitors
ES2386299T3 (es) 2006-02-03 2012-08-16 Bionomics Limited Benzofuranos, benzotiofenos, benzoselenofenos e indoles sustituidos y su uso como inhibidores de la polimerización de tubulina
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
AU2008280257A1 (en) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Benzofuran- and benzo[B]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2010093578A1 (en) 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
EP2427430B1 (en) 2009-05-04 2014-09-10 The Royal Institution for the Advancement of Learning/McGill University 5-oxo-ete receptor antagonist compounds
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
CA2798074A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
JP2013528223A (ja) 2010-06-10 2013-07-08 アラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2012048058A2 (en) 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
EP2655367B1 (en) 2010-12-24 2016-07-06 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
WO2013116293A1 (en) 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
NZ630124A (en) 2012-03-20 2016-01-29 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2871891B1 (en) 2012-08-01 2017-03-29 Huawei Technologies Co., Ltd. Synchronization method, apparatus, and system
EP2892826A1 (en) 2012-09-05 2015-07-15 Koninklijke Philips N.V. Capsule for the preparation of beverages, device and method
EP2911660B1 (en) 2012-10-24 2019-12-04 The Board of Trustees of the University of Illionis Compositions and methods for treating estrogen-related medical disorders
CA2928131C (en) 2012-10-24 2023-02-07 The Board Of Trustees Of The University Of Illinois Benzothiophene derivatives and use thereof for treating estrogen-related medical disorders
MX359471B (es) * 2013-02-19 2018-09-28 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrogeno.
CA2899969A1 (en) 2013-03-14 2014-09-25 Seragon Pharmaceuticals, Inc. Polycyclic estrogen receptor modulators and uses thereof
LT3004090T (lt) 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
JP6576916B2 (ja) 2013-06-19 2019-09-18 セラゴン ファーマシューティカルズ， インク． エストロゲン受容体モジュレーター及びその使用
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN105451735B (zh) 2013-06-19 2019-01-11 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
SMT202300072T1 (it) 2014-03-28 2023-05-12 Univ Duke Cancro della mammella mediante l'utilizzo di modulatori selettivi del recetiore degli estrogeni
CN107108611B (zh) 2014-12-18 2020-09-25 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
EP3303326B1 (en) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
RU2730508C2 (ru) 2015-06-16 2020-08-24 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное пиперидина, способ его получения и его фармацевтическое применение
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
WO2017056115A1 (en) 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
US9975856B2 (en) 2015-10-07 2018-05-22 Genentech, Inc. Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
RS63217B1 (sr) 2015-10-27 2022-06-30 Sun Pharma Advanced Res Co Ltd Novi heterociklični antiestrogeni
HK1258851A1 (zh) 2015-11-09 2019-11-22 豪夫迈‧罗氏有限公司 四氢萘雌激素受体调节剂及其用途
JP6592197B2 (ja) 2015-11-12 2019-10-16 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アクリル酸誘導体、製造方法、および医薬としてのその使用
WO2017100715A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CA3048057A1 (en) 2017-01-06 2018-07-12 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
CA3008020C (en) 2024-02-20
ZA201803422B (en) 2020-08-26
AU2016366680B2 (en) 2021-06-24
EP3386968A1 (en) 2018-10-17
WO2017100715A1 (en) 2017-06-15
MX2020006991A (es) 2022-07-14
US20200123126A1 (en) 2020-04-23
EP3386968B1 (en) 2025-04-02
US20190055209A1 (en) 2019-02-21
US10377735B2 (en) 2019-08-13
KR20180088457A (ko) 2018-08-03
CA3008020A1 (en) 2017-06-15
DK3386500T3 (da) 2022-12-12
WO2017100712A1 (en) 2017-06-15
US11447461B2 (en) 2022-09-20
NZ743651A (en) 2023-07-28
BR112018011607A2 (pt) 2018-11-27
EA201891376A1 (ru) 2019-02-28
HUE061065T2 (hu) 2023-05-28
US12054469B2 (en) 2024-08-06
US11072595B2 (en) 2021-07-27
JP2021169498A (ja) 2021-10-28
US20220194917A1 (en) 2022-06-23
PT3386500T (pt) 2023-01-06
CN108495628B (zh) 2022-01-11
SMT202300018T1 (it) 2023-03-17
US20200079752A1 (en) 2020-03-12
CN108699024B (zh) 2022-03-11
BR112018011607B1 (pt) 2024-01-30
US20170166551A1 (en) 2017-06-15
SI3386500T1 (sl) 2023-01-31
JP2019502675A (ja) 2019-01-31
CN108495628A (zh) 2018-09-04
EP3386968A4 (en) 2019-09-25
EP3386500A4 (en) 2019-05-22
ES2935125T3 (es) 2023-03-01
MX2018007079A (es) 2018-11-12
US20170166550A1 (en) 2017-06-15
MX393926B (es) 2025-03-24
KR102785173B1 (ko) 2025-03-25
MX373946B (es) 2020-07-13
US10807964B2 (en) 2020-10-20
EP3386500A1 (en) 2018-10-17
EA038180B1 (ru) 2021-07-20
LT3386500T (lt) 2022-12-27
RU2018125046A3 (pl) 2020-02-10
IL259566B (en) 2021-09-30
US10118910B2 (en) 2018-11-06
CN108699024A (zh) 2018-10-23
US20210047286A1 (en) 2021-02-18
RU2018125046A (ru) 2020-01-09
RS63791B1 (sr) 2022-12-30
HRP20221462T1 (hr) 2023-01-20
JP6920709B2 (ja) 2021-08-18
RU2747802C2 (ru) 2021-05-14
ZA202003023B (en) 2022-12-21
IL259566A (en) 2018-07-31
EP3386500B1 (en) 2022-09-07
AU2016366680A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
ZA202003023B (en) Benzothiophene-based selective estrogen receptor downregulators
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
IL258092A (en) Glucagon receptor agonists
GB201522592D0 (en) T cell receptors
SG11201708313QA (en) T cell receptor
GB201702617D0 (en) Receptor
PL3529267T3 (pl) Receptor komórek t
ZA201800181B (en) Sanitary-ware flushing system
PL3150781T3 (pl) Zespół kabin sanitarnych
PL3155011T3 (pl) Mutacje receptora hormonu glikoproteinowego
GB2542922B (en) Support Harness
GB201510811D0 (en) Mixing device
GB2544560B (en) Mixing bowl
HUE052830T2 (hu) Keverõszerkezet
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
PL3500265T3 (pl) Selektywne ligandy receptora estrogenowego beta
GB201518991D0 (en) T cell receptors
GB201515020D0 (en) Seat
GB201504285D0 (en) Receptor modulation
GB201520136D0 (en) Fixing device for chairs
HUP1500233A2 (hu) Volfrám alapú metatézis katalizátorok
AU361668S (en) A swinging seat